Every biopharma pitch (once indications are chosen) should include some discussion of the patient journey, even for well-known diseases. This serves some obvious purposes – e.g., providing context for clinical trial design and supporting the commercial opportunity. But...1/4
...an often overlooked benefit is that it helps investors establish an emotive connection to the drug program. Importantly, elucidating the patient journey is more than just describing the pathogenesis, progression, and treatment options of a disease; it’s helping people...2/4
...understand the challenges patients face, and why these would motivate them to try a new drug. When driven by a sincere interest to make a difference for patients, investors and entrepreneurs alike are more willing to take certain risks and are more resilient in the...3/4
...face of the ups and downs of drug development. Similarly, it’s a positive signal when VCs see a management team with passion that extends beyond their love for the science to commitment to the patient community. 4/4